This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://linked.opendata.cz/resource/drugbank/drug/DB00633/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00633/identifier/chebi/
n13http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00633/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00633/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n21http://www.rxlist.com/cgi/generic/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00633/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00633/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00633/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00633
rdf:type
n5:Drug
n5:description
An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem]
n5:dosage
n7:271B5C4C-363D-11E5-9242-09173F13E4C5 n7:271B5C4D-363D-11E5-9242-09173F13E4C5 n7:271B5C4E-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
2 hours
n5:indication
For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia
n5:manufacturer
n17:271B5C4A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00633 n13:DB00633
dcterms:title
Dexmedetomidine
adms:identifier
n4:0409-1638-02 n15:Dexmedetomidine n18:DB00633 n19:C07450 n22:4466 n23:PA449256 n24:D00514
n5:mechanismOfAction
Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.
n5:packager
n17:271B5C48-363D-11E5-9242-09173F13E4C5 n17:271B5C49-363D-11E5-9242-09173F13E4C5
n5:patent
n8:5344840 n8:6716867 n8:1337659 n8:2326339
n5:routeOfElimination
A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. The majority of metabolites are excreted in the urine.
n5:synonym
(S)-medetomidine (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole Dexmedetomidinum MPV 1440 Dexmédétomidine (+)-medetomidine Dexmedetomidin Dexmedetomidina
n5:volumeOfDistribution
* 118 L
n5:proteinBinding
94%
n5:salt
n5:synthesisReference
Inese Reine, Armands Zandersons, "METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS.." U.S. Patent US20100048915, issued February 25, 2010.
n25:hasConcept
n26:M0140432
foaf:page
n21:precedex.htm
n5:IUPAC-Name
n6:271B5C53-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5C59-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5C58-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5C55-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5C56-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5C57-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5C51-363D-11E5-9242-09173F13E4C5 n6:271B5C69-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5C52-363D-11E5-9242-09173F13E4C5 n6:271B5C6A-363D-11E5-9242-09173F13E4C5 n6:271B5C4F-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5C50-363D-11E5-9242-09173F13E4C5
n5:pKa
n6:271B5C6B-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:N05CM18
n5:H-Bond-Acceptor-Count
n6:271B5C5F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5C60-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5C5A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5C5B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5C5D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5C5C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5C5E-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
113775-47-6
n5:category
n5:clearance
* 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)]
n5:containedIn
n16:271B5C4B-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5C65-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5C67-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5C68-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5C64-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5C63-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5C66-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5C54-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5C61-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5C62-363D-11E5-9242-09173F13E4C5